FOLITRAX LP GEL contains methotrexate, an antimetabolite with anti-inflammatory and antiproliferative properties. When applied topically, methotrexate acts on affected skin and may help reduce abnormal cellular proliferation associated with psoriatic plaques.
The product may be considered for patients:
Clinical studies of topical methotrexate have produced promising results in localized psoriasis. A 2006 study involving 40 patients evaluated 1% methotrexate gel applied twice daily for 8 weeks. At the end of treatment, complete clearance of erythema was reported in 47.5% of patients on the methotrexate-treated lesions compared with 7.5% with placebo, while overall clinical improvement was also greater with methotrexate. (PubMed)
An earlier double-blind pilot study evaluating topical methotrexate at different concentrations also reported improvement in psoriatic lesions compared with the inactive vehicle. (PubMed)
A 2022 comparative study evaluated 1% topical methotrexate gel against calcipotriol in localized plaque psoriasis. After 12 weeks, marked-to-complete improvement was reported in 97.5% of lesions treated with methotrexate compared with 37.5% with calcipotriol, with findings supported by clinical, dermoscopic, and histopathological assessments. (Wiley Online Library)
Studies have also investigated topical 1% methotrexate compared with potent topical corticosteroids. However, the evidence base for topical methotrexate is substantially smaller than that for systemic methotrexate and established approved psoriasis therapies. Treatment should therefore be used only under appropriate medical supervision. (PubMed Central (PMC))
The product is primarily used for the topical treatment of localized manifestations of chronic plaque psoriasis. Methotrexate suppresses processes associated with excessive cellular proliferation and inflammatory activity, helping reduce the thickness, redness, and scaling of psoriatic plaques.
Topical methotrexate should not be considered a universal replacement for systemic therapy or established topical treatments. Treatment selection depends on disease extent, severity, and the patient's individual clinical condition.
The gel should be applied as a thin layer directly to affected areas of the skin according to the dermatologist's instructions. Frequency of application and treatment duration should be individualized according to disease severity and the patient's response. The amount applied, frequency, or treated surface area should not be increased without medical advice. Avoid contact with the eyes and mucous membranes and avoid application to damaged skin unless specifically directed by a healthcare professional.
Side Effects
